Polaris Partners

Cohere Health's Utilization Management Platform Earns HITRUST r2 Certification

Retrieved on: 
Wednesday, August 17, 2022
Utilization management, NIST, Risk, Technology, CB Insights, Quality assurance, Achievement, GDPR, Software as a service, Health, National Committee, Patient, Certification, Polaris Partners, Accreditation, PCI, HIPAA, Scalable Coherent Interface, Privacy, National Committee for Quality Assurance, Physician, ISO, Digital, HITRUST, Organization, Medical device, Quality

BOSTON, Aug. 17, 2022 /PRNewswire/ -- Today Cohere Health, a recognized leader in intelligent utilization management (UM) technology, announced that its UM collaboration platform has received Certified status for information security by HITRUST. This coveted designation places Cohere in an elite group of organizations that have demonstrated the utmost commitment to security, privacy, and regulatory compliance best practices.

Key Points: 
  • "Achieving HITRUST certification shows that we're at the forefront of providing the highest standards of data security and protection," said Niall O'Connor, Chief Technology Officer, Cohere Health.
  • Certification demonstrates that Cohere's platform meets all national and international security, privacy, and regulatory standards, including ISO, NIST, PCI, HIPAA, and GDPR.
  • Cohere is one of the few companies focused on UM to earn HITRUST r2certification, and was also the first digital prior authorization platform to achieve Utilization Management Accreditation from the National Committee for Quality Assurance.
  • To maintain HITRUST certification, Cohere must ensure regular third-party monitoring of its intelligent UM collaboration platform, including the testing of hundreds of security controls.

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Retrieved on: 
Thursday, August 4, 2022
People, Orpheus, Disorder, Tuberous sclerosis complex tumor suppressors, Disability, Glutamate (neurotransmitter), Patient, Stuttering, Company, Neurodevelopmental disorder, CNS, Pain, Safety, FDA, Seizure, Adolescence, Solution, Work, Insulin resistance, GLOBE, PDE10A, Person, Sofinnova, Central nervous system, Â, Neuron, Trigeminal neuralgia, Tourette syndrome, Employment, Ageing, Polaris Partners, Basimglurant, COFD, Population, Pharmaceutical industry, Biotechnology, MD

Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "Recruiting the first participant is an important step in the clinical investigation of gemlapodect in this indication.
  • "Our main goal is to evaluate the safety and efficacy of gemlapodect as a monotherapy for COFD in adults.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Lob Survey Reinforces Power of Direct Mail, Finding 85% of Consumers Regularly Read Direct Mail Received from Brands and 62% Have Taken Action

Retrieved on: 
Wednesday, July 27, 2022
Acquisition, Y Combinator, Intelligence, Polaris Partners, Industry, SAN, Friends, Ageing, Partnership, Solution, Mintel, CMO, Income, Adult, Family, Technology, Printing, Local Business, Perception, Communication, First Round Capital, Automation, ROI, Financial services, Retail, Online shopping, Sales, Mail, Health care, Lob, Research, Floodgate

SAN FRANCISCO, July 27, 2022 /PRNewswire/ -- Lob, the leading direct mail automation platform, today unveiled a report on the State of Direct Mail Consumer Insights, in partnership with Comperemedia. The report surveyed 2,111 adult (aged 18+) consumers in the U.S. and uncovered consumers' perception and attitudes towards direct mail and how brands communicate and engage their customers, revealing a strong preference for receiving physical mail. The survey found that over 85% of consumers regularly read direct mail received from brands either immediately, on the same day, or at a later time, with 62% reporting a direct mailpiece has inspired action.

Key Points: 
  • The survey found that over 85% of consumers regularly read direct mail received from brands either immediately, on the same day, or at a later time, with 62% reporting a direct mailpiece has inspired action.
  • Building on the direct mail channel's prominence in the marketing strategy mix, the survey found direct mail is critical to the acquisition and retention of customers, with almost half of consumers being introduced to new brands via direct mail.
  • Sixty-six percent of consumers reported they are likely engaging with and act on direct mail from brands they already have a relationship with, proving direct mail is integral throughout the entire customer journey.
  • The findings in the State of Direct Mail Consumer Insights Report prove intelligent direct mail that is connected, personalized, and measurable resonates with consumers.

Leeds Equity Partners Announces Sale of Amplifire to Polaris Partners

Retrieved on: 
Monday, July 25, 2022
Knowledge, Sale, Algorithm, Knowledge industries, Health care, Education, Leeds Equity Partners, Learning, IEEE 802.1X, Partnership, Organization, Company, Software as a service, Growth, Cognitive science, Financial services, Tutoring, Polaris Partners, Amplifier

NEW YORK, July 25, 2022 /PRNewswire/ -- Leeds Equity Partners ("Leeds Equity"), the New York-based private equity firm focused exclusively on investing in the Knowledge Industries, announced the sale of its portfolio company Knowledge Factor, Inc. ("Amplifire," or the "Company"), a leading SaaS provider of cognitive science-based assessment, training, and data analytics, to Polaris Partners.

Key Points: 
  • NEW YORK, July 25, 2022 /PRNewswire/ -- Leeds Equity Partners ("Leeds Equity"), the New York-based private equity firm focused exclusively on investing in the Knowledge Industries, announced the sale of its portfolio company Knowledge Factor, Inc. ("Amplifire," or the "Company"), a leading SaaS provider of cognitive science-based assessment, training, and data analytics, to Polaris Partners.
  • Canaccord Genuity served as financial advisor to Amplifire and Leeds Equity Partners.
  • Amplifire, founded in 2000, is headquartered in Boulder, CO.
    Leeds Equity Partners is a private equity firm dedicated exclusively to partnering with management teams in the education, training, and information services industries (the "Knowledge Industries").
  • Leeds Equity seeks to leverage its sector-focused expertise and market insights to create long-term value for its partner companies.

Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform

Retrieved on: 
Wednesday, July 20, 2022
Neoplasm, GLOBE, Norwest Venture Partners, Polaris Partners, CEO, Research, Drug discovery, UCLA, Therapy, Board, Cancer, American Cancer Society, Machine learning, Eli Lilly and Company, Company, Patient, Growth, Pharmaceutical industry, Vaccine, Auron

Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery.

Key Points: 
  • Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery.
  • Dr. Eric Shiozaki, Ph.D., Partner at DCVC Bio and Dr. Alexandra Cantley, Ph.D., Partner at Polaris Partners will be joining the Companys Board of Directors.
  • Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression, said Dr.
  • Auron Therapeutics is shifting the paradigm of cancer treatment to target key drivers of dysregulated differentiation and cellular plasticity in tumors.

CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic

Retrieved on: 
Wednesday, July 20, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Gene expression, Polaris Partners, Dravet syndrome, Protein, Kraft Group, RNA, CEO, Series, RAP, Lists of diseases, Therapy, ENAV, Gene, Central nervous system, Liver, Disease, Asos, Patient, ASO, Molecular biology, Vaccine, Pharmaceutical industry, Genome

Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group, and others also joined the round.

Key Points: 
  • Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group, and others also joined the round.
  • Through breakthroughs in molecular biology, it is now known that regRNAs control the expression of nearby protein-encoding genes.
  • This approach is applicable to a range of genetic diseases in which tunable increases in gene output can lead to meaningful therapeutic outcomes.
  • Were excited to lead this financing and partner with CAMP4 to help realize the full potential of RNA actuators for patients with genetic diseases.

Geisinger and Cohere Health Join in Driving High-Value Care and Reducing Provider Burden

Retrieved on: 
Tuesday, July 12, 2022
Technology, GHP, Geisinger Commonwealth School of Medicine, Health, Commercial, LinkedIn, Medicare Advantage, J.D. Power, Digital, Medicaid, Patient, Friction, CEO, CB Insights, MD, Instagram, Physician, Population, Geisinger Health System, Medicare, Commercial Exchange Building (Jackson, Michigan), Research, Twitter, Polaris Partners, Industry, Health insurance, Medicine, Medical device, Geisinger, Intracoronary optical coherence tomography, Facebook

DANVILLE, Pa. and BOSTON, July 12, 2022 /PRNewswire/ -- Today Geisinger Health Plan (GHP) and Cohere Health, a recognized leader in utilization management (UM) technology, announced they are joining forces to drive high-value care and reduce provider burden. Cohere's collaborative UM platform will help GHP support value-based care delivery, reduce administrative costs, and lead the nation in aligning quality improvement initiatives across all its lines of business, including Commercial, Exchange, Medicare Advantage, and the newly expanded Medicaid.

Key Points: 
  • DANVILLE, Pa. and BOSTON, July 12, 2022 /PRNewswire/ --Today Geisinger Health Plan (GHP) and Cohere Health, a recognized leader in utilization management (UM) technology, announced they are joining forces to drive high-value care and reduce provider burden.
  • "Working with Cohere Health is a transformational step in Geisinger's long history of clinical innovation, both in Pennsylvania and nationwide," said John Bulger, MD, chief medical officer for Geisinger Health Plan.
  • "We're thrilled to work with Geisinger Health Plan on a digital-first approach to transforming utilization management that furthers their mission: providing members with high-quality, affordable care," said Siva Namasivayam, CEO of Cohere Health.
  • Cohere Health is a digital intelligence company that's transforming utilization management (UM) by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey.

Nomad Health Raises $105 Million to Expand to New Specialties and Address Healthcare Staffing Crisis

Retrieved on: 
Monday, June 27, 2022
Nursing, Education, Health, Hospitals, COVID-19, General Health, University, Therapy, Icon, San Francisco Bay Area, Venture round, Ageing, Patient, CEO, Nazim, Polaris Partners, Travel, Health, Nomad Health, TDOC, Â, Aster Data Systems, Marketing, COVID-19, Population, Growth, PANW, House at 6 Adams Street, Icon Ventures, INFN, J. P. Morgan, Joint Commission, FireEye, MBA, M.B.A, Investment, News Corp, Technology, Doctor of Philosophy, Teradata, Board, Overstock.com, Twitter, Data science, Hospital, Financial services, Pharmaceutical industry, Management, MD, Infinera, Move (company), Experian

Nomads latest financing round comes as the healthcare staffing crisis reaches a new high.

Key Points: 
  • Nomads latest financing round comes as the healthcare staffing crisis reaches a new high.
  • The COVID-19 pandemic has exposed and accelerated the healthcare workforce crisis that has been a powerful undercurrent in healthcare for decades.
  • Nomad Health is truly revolutionizing the healthcare staffing experience, said Maquel Shaw, Chief Marketing Officer at Nomad Health.
  • Nomad Health is a Joint Commission Certified technology company that is simplifying the $40 billion healthcare staffing industry.

Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

Retrieved on: 
Monday, June 27, 2022
People, Efficiency, FDA, Patient, Sofinnova, Glutamate (neurotransmitter), Basimglurant, Neurodevelopmental disorder, Polaris Partners, TSC, Biology, Investigational New Drug, GLOBE, CNS, Company, Orpheus, PDE10A, Trigeminal neuralgia, Ageing, Disorder, IND, Disability, Neuron, Seizure, COFD, Tuberous sclerosis complex tumor suppressors, US Foods, Tourette syndrome, Safety, Insulin resistance, Work, Pharmaceutical industry, Noema, Biotechnology, Stuttering, Research, MD

The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "We have great confidence that gemlapodect will help people who stutter maximize their ability to live life to the fullest."
  • Noema Pharma ( www.noemapharma.com ) is a clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications characterized by imbalanced neuronal networks.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Thrive Pet Healthcare and FidoCure® Announce An Expansive Pet Precision Health Partnership

Retrieved on: 
Wednesday, June 22, 2022
Dog, Data, Canine cancer detection, Global brain, Industry, Thrive, PALO, PETS, CEO, Parent, Precision medicine, Cancer, Human, Research, Growth, Y combinator, Polaris Partners, Health, Federation of National Specialty Societies of Canada, Partnership, Veterinary medicine, Patient, Love, Medical imaging, Vaccine, Pet

AUSTIN, Texas and PALO ALTO, Calif., June 22, 2022 /PRNewswire-PRWeb/ -- Thrive Pet Healthcare, a national veterinary hospital network offering a comprehensive continuum of care for pets, and FidoCure, the leading pet precision health company, today announced a strategic partnership which advances a joint vision for providing personalized, accessible veterinary cancer care. This partnership leverages FidoCure's cutting edge precision medicine platform and unparalleled algorithmic driven diagnostics to improve outcomes in pets with cancer across Thrive Pet Healthcare's nationwide network of over 350 veterinary care clinics.

Key Points: 
  • By establishing access to FidoCure within its nationwide ecosystem, Thrive Pet Healthcare can provide cutting-edge cancer care to more dogs than any other veterinary clinic network.
  • This partnership between FidoCure and Thrive Pet Healthcare means that more pet parents will have streamlined access to this cutting-edge cancer care platform, providing the best possible care to dogs that they love," said Christina K. Lopes, co-founder and CEO of FidoCure.
  • This partnership with FidoCure will enable Thrive Pet Healthcare clinicians across the country to better fulfill our mission of providing comprehensive pet care at every stage of life.
  • Thrive Pet Healthcare is a leading veterinary service network that uniquely delivers a continuum of care to pet families and services to veterinary hospitals.